The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework

Y Lin, C J Moltzan, D R Anderson, National Advisory Committee on Blood and Blood Products, Lucinda Whitman, David Anderson, Ted Alport, Jeannie Callum, Karen Dallas, Dana Devine, Cheryl Doncaster, Jennifer Fesser, David Howe, Elenore Kingsbury, Debra Lane, Vincent Laroche, Doug Morrison, Brian Muirhead, Susan Nahirniak, Katerina Pavenski, Tanya Petraszko, Lakshmi Rajappannair, Meer-Taher Shabani-Rad, Y Lin, C J Moltzan, D R Anderson, National Advisory Committee on Blood and Blood Products, Lucinda Whitman, David Anderson, Ted Alport, Jeannie Callum, Karen Dallas, Dana Devine, Cheryl Doncaster, Jennifer Fesser, David Howe, Elenore Kingsbury, Debra Lane, Vincent Laroche, Doug Morrison, Brian Muirhead, Susan Nahirniak, Katerina Pavenski, Tanya Petraszko, Lakshmi Rajappannair, Meer-Taher Shabani-Rad

Abstract

In 2006, the Canadian National Advisory Committee on Blood and Blood Products (NAC) developed a transfusion policy framework for the use of off-label recombinant factor VIIa (rFVIIa) in massive bleeding. Because the number of randomised controlled trials has doubled, the NAC undertook a review of the policy framework in 2011. On the basis of the review of 29 randomised controlled trials, there remains little evidence to support the routine use of rFVIIa in massive bleeding. Mortality benefits have not been demonstrated. Contrarily, an increase in arterial thromboembolic events has been observed with the use of off-label rFVIIa. Given the absence of evidence of benefit and with evidence of the risk of harm, the NAC recommends that recombinant VIIa no longer be used for the off-label indications of prevention and treatment of bleeding in patients without haemophilia.

© 2012 The Authors. Transfusion Medicine © 2012 British Blood Transfusion Society.

Figures

Fig. 1
Fig. 1
Trend in recombinant factor VIIa issues by Canadian Blood Services (courtesy of Canadian Blood Services).

References

    1. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. The Journal of Trauma. 2005;59:8–15. discussion 15-8.
    1. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology (Baltimore, Md.) 2008;47:1604–1614.
    1. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123–1130.
    1. Cameron P, Phillips L, Balogh Z, Joseph A, Pearce A, Parr M, Jankelowitz G. The use of recombinant activated factor VII in trauma patients: experience from the Australian and New Zealand haemostasis registry. Injury. 2007;38:1030–1038.
    1. Center for Biologics Evaluation and Research, US Food and Drug Administration. 1999. Novoseven Product Information [WWW document]. URL (Accessed 10/01/12)
    1. Chuansumrit A, Wangruangsatid S, Lektrakul Y, Chua MN, Zeta Capeding MR, Bech OM, Dengue Study Group Control of bleeding in children with dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis. 2005;16:549–555.
    1. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. British Journal of Anaesthesia. 2005;95:596–602.
    1. Dzik WH. Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII. Journal of Intensive Care Medicine. 2006;21:54–59.
    1. Dzik WH, Blajchman MA, Fergusson D, et al. Clinical review: Canadian National Advisory Committee on Blood and Blood Products – Massive Transfusion Consensus Conference 2011: Report of the panel. Critical Care. 2011;15:242. [Epub ahead of print]
    1. Ekert H, Brizard C, Eyers R, Cochrane A, Henning R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis. 2006;17:389–395.
    1. Essam MA. Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery. Internet Journal of Anesthesiology. 2007;13:10.
    1. Flaherty ML, Jauch EC. 2011. The Spot Sign for Predicting and Treating ICH Growth Study (STOP-IT) [WWW document]. URL (Accessed 10/01/12)
    1. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201–205.
    1. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation. 2009;120:21–27.
    1. Gladstone DJ, Aviv RI, Demchuk AM. 2011. “Spot sign” selection of intracerebral hemorrhage to guide hemostatic therapy (SPOTLIGHT) [WWW document]. URL (Accessed 10/01/12)
    1. Hanna MG, Refaie A, Gouda N, Obaya G. Reduction of peri-operative bleeding in craniofacial surgeries in pediatrics: comparison between recombinant factor VII and tranexamic acid. Egyptian Journal of Anaesthesia. 2010;26:53–61.
    1. Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. The Journal of Trauma. 2010;69:489–500.
    1. Health Canada. 2005. Notice of Compliance with Conditions (NOC/c) [WWW document]. URL (Accessed 10/01/12)
    1. Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand haemostasis register. Internal Medicine Journal. 2008;38:156–165.
    1. Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology. 2002;123:118–126.
    1. Johansson PI, Eriksen K, Nielsen SL, Rojkjaer R, Alsbjorn B. Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting – results of a single centre pilot study. Burns : Journal of the International Society for Burn Injuries. 2007;33:435–440.
    1. Karkouti K, Beattie WS, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation. 2008;118:331–338.
    1. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879.
    1. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. The New England Journal of Medicine. 2010;363:1791–1800.
    1. Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2005a;11:973–979.
    1. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005b;102:269–275.
    1. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Annals of Internal Medicine. 2011;154:516–522.
    1. Ma B, Wang ZN, Zhang BR, Xu ZY, Yang LX, Chen KB, Li J. Effect of recombinant activated factor VIIa on early recovery of patients undergoing cardiac valve replacement under cardiopulmonary bypass: a randomized double-blind placebo-controlled trial. Academic Journal of Second Military Medical University. 2006;27:1110–1113.
    1. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. The New England Journal of Medicine. 2005a;352:777–785.
    1. Mayer SA, Brun NC, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T, Europe/AustralAsia NovoSeven ICH Trial Investigators Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke: A Journal of Cerebral Circulation. 2005b;36:74–79.
    1. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. The New England Journal of Medicine. 2008;358:2127–2137.
    1. Mayer SA, Brun NC, Broderick J, Davis SM, Diringer MN, Skolnick BE, Steiner T, United States NovoSeven ICH Trial Investigators Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocritical Care. 2006;4:206–214.
    1. Meng ZH, Wolberg AS, Monroe DM, 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. The Journal of Trauma. 2003;55:886–891.
    1. Moltzan CJ, Anderson DA, Callum J, et al. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework. Transfusion Medicine (Oxford, England) 2008;18:112–120.
    1. Narayan RK, Maas AI, Marshall LF, Servadei F, Skolnick BE, Tillinger MN, rFVIIa Traumatic ICH Study Group Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery. 2008;62:776–786. discussion 786-8.
    1. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA: The Journal of the American Medical Association. 2006;295:293–298.
    1. Phillips LE, Zatta A, Kandane-Rathnayake R, Aoki N, on behalf of the Haemostasis Registry Steering Committee 2011. Haemostasis registry final report: ten years of data on the use of recombinant activated factor VII in Australia and New Zealand Monash University.
    1. Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L, Brenner B, F7BMT-1360 Trial Investigators Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. Journal of Thrombosis and Haemostasis: JTH. 2005;3:1935–1944.
    1. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2005;11:895–900.
    1. Pugliese F, Ruberto F, Summonti D, et al. Activated recombinant factor VII in orthotopic liver transplantation. Transplantation Proceedings. 2007;39:1883–1885.
    1. Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. British Journal of Anaesthesia. 2005;94:586–591.
    1. Sachs B, Delacy D, Green J, et al. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. Spine. 2007;32:2285–2293.
    1. Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, Nivatvongs S, Lee PH. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. American Journal of Surgery. 2006;191:245–249.
    1. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. 2012. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD005011.
    1. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Annals of Internal Medicine. 2011;154:529–540.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa